TONIX PHARMACEUTICALS HOLDING CORP. Cash and Restricted Cash
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) had Cash and Restricted Cash of $176.62 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-10
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $176.62M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $186.01M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $209.81M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $191.35M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $176.62M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $186.01M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $209.81M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $191.35M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $126.24M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $132.62M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $99.68M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $29.14M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $5.06M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $7.95M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $25.85M 10-K · filed 2026-03-12 |
| 2023-09-30 | $7.92M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $25.86M 10-Q · filed 2024-08-16 |
| 2023-03-31 | $72.22M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $120.47M 10-K · filed 2025-03-18 |
| 2022-09-30 | $140.22M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $177.22M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $140.68M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $178.90M 10-K · filed 2024-04-01 |
| 2021-09-30 | $183.21M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $165.96M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $164.45M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $77.31M 10-K · filed 2023-03-13 |
| 2020-09-30 | $55.90M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $55.12M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $30.77M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $11.35M 10-K · filed 2022-03-14 |
| 2019-09-30 | $10.12M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $12.25M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $16.55M 10-Q · filed 2020-05-12 |
| 2018-12-31 | $25.13M 10-K · filed 2021-03-15 |
| 2018-09-30 | $14.77M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $16.77M 10-Q · filed 2019-08-12 |
| 2018-03-31 | $19.34M 10-Q · filed 2019-05-13 |
| 2017-12-31 | $25.59M 10-K · filed 2020-03-24 |
| 2017-09-30 | $29.40M 10-Q · filed 2018-11-09 |
| 2017-06-30 | $34.44M 10-Q · filed 2018-08-13 |
| 2017-03-31 | $20.03M 10-Q · filed 2018-05-11 |
| 2016-12-31 | $19.03M 10-K · filed 2019-03-18 |
| 2015-12-31 | $19.31M 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |